Can-Fite BioPharma Ltd. Stock Price, News & Analysis

Can-Fite BioPharma (NYSE: CANF) announced that Dr. Kim A. Papp will present findings from the Phase III COMFORT study at the 31st EADV Congress in Milan on September 10, 2022. The study showed that Piclidenoson significantly improved psoriasis symptoms compared to placebo. Dr. Papp, a leading expert with over 150 studies, is also designing a pivotal Phase III trial for FDA and EMA submission. Can-Fite's drug candidate is positioned to address severe psoriasis, leveraging its unique mechanism of action to inhibit inflammatory cytokines.

Can-Fite BioPharma (NYSE American: CANF) announced the completion of a safety study for Piclidenoson, a treatment for canine osteoarthritis. The efficacy trial will be financed by Vetbiolix, which holds exclusive rights to Piclidenoson for two years. The global market for canine osteoarthritis is anticipated to reach $3 billion by 2028. If successful, Vetbiolix will pay Can-Fite milestone and royalty fees upon regulatory approval. Piclidenoson aims to provide a safer alternative to current NSAID treatments.

Can-Fite BioPharma (CANF) plans to submit registration plans for its lead drug Piclidenoson to the FDA and EMA for treating moderate to severe psoriasis. The company reported positive topline results from its Phase III COMFORT study, demonstrating significant improvement over placebo and a favorable safety profile compared to Otezla. Notably, only 1% of Piclidenoson patients experienced gastrointestinal issues, versus 6% for Otezla. The study involved over 400 patients and showed that those with higher disease severity benefited more from Piclidenoson. Can-Fite aims for strong market positioning with this candidate.

Can-Fite BioPharma reports positive results from its Phase III COMFORT™ trial for Piclidenoson, a treatment for moderate to severe plaque psoriasis. The primary endpoint was met, with significant improvement observed in patients receiving a 3 mg dosage compared to placebo at week 16 (9.7% vs. 2.6%, P<0.04). Piclidenoson demonstrated an excellent safety profile, better than Otezla. Can-Fite plans to approach the FDA and EMA for further studies. The company holds five licensing agreements globally for Piclidenoson.

Can-Fite BioPharma (NYSE American: CANF) has announced that their study on CF602, an allosteric modulator of the A3 adenosine receptor, has been published in the journal Andrologia. The study demonstrates that CF602 effectively reverses erectile dysfunction (ED) in a diabetic rat model, showing potential as an alternative treatment for the estimated 30-35% of ED patients who are non-responders to standard PDE5 inhibitors like Viagra and Cialis. The global ED market is valued at $3.6 billion and projected to grow to $5.94 billion by 2028.

Can-Fite BioPharma (NYSE American: CANF) has published an article on A3 Adenosine Receptor-targeting drugs in MDPI's journal Molecules. The data supports the potential of Piclidenoson and Namodenoson as frontrunners for FDA approval, showcasing their efficacy against psoriasis, liver cancer, and NASH. Can-Fite's extensive clinical data involves over 1,500 patients across multiple trials, with current studies including a Phase III for psoriasis and a Phase IIb for NASH. The company has received regulatory designations for its drug candidates that address significant market needs.

Can-Fite BioPharma Ltd. (NYSE American: CANF) reported its financial results for Q1 2022, with revenues of $0.20 million, up 38.5% from $0.15 million in Q1 2021. The company holds $16.5 million in cash and equivalents. R&D expenses rose 39.8% to $1.82 million due to ongoing clinical trials for psoriasis and NASH treatments. The net loss increased to $2.43 million from $1.87 million year-on-year. Upcoming milestones include Phase III psoriasis study results expected in Q2 2022 and ongoing Phase IIb and III studies for NASH and liver cancer.

Can-Fite BioPharma Ltd. (NYSE American: CANF) has received a patent for its A3 Adenosine Receptor ligand aimed at treating ectopic fat accumulation, particularly in non-alcoholic steatohepatitis (NASH) and fatty liver disease. The patent is recognized in about 40 countries, including Japan and the EU. The market for NASH treatment is expected to reach $35 billion by 2025. Can-Fite is currently conducting a Phase IIb clinical trial for its drug candidate Namodenoson, which previously met key endpoints in Phase IIa trials, showing safety and efficacy in reducing liver fat.

Can-Fite BioPharma (NYSE American: CANF) announced a Phase II study where Namodenoson, an oral drug targeting liver cancer, cleared all lesions in an advanced patient. The pivotal Phase III trial has received FDA and EMA approval and is now open to recruit around 450 hepatocellular carcinoma patients. The drug selectively binds to the A3 adenosine receptor, prevalent in cancer cells. CEO Dr. Pnina Fishman is set to present at the Adenosine Pathway Targeted Cancer Immunotherapy Summit in Boston on May 12, 2022, highlighting the drug's promising results.